Weight-loss drugs, including Ozempic, are reshaping consumer habits. Additionally, they are providing some ballast to what’s recently been a sluggish healthcare investment thesis. Tactical investors know that when it comes to drugs or therapies, regardless of underlying usage case, it’s best to play related developments with assets that seize upon those themes. That’s likely one [...] The post Weight-Loss Drugs Boost Case for Pharma ETFs appeared first on ETF Trends .